Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels

Clinical Proteomics

Volumn 8, Issue 1, 2011, Pages

  Arentz, Georgia ^a,b   Chataway, Tim ^c   Price, Timothy J ^a,b   Izwan, Zaipul ^a,b   Hardi, Gemma ^a,b   Cummins, Adrian G ^a,b   Hardingham, Jennifer E ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

2D DIGE; angiogenesis; biomarker; Colorectal cancer; desmin; pericyte

Indexed keywords

BIOLOGICAL MARKER; DESMIN; TUMOR PROTEIN; VIMENTIN; VON WILLEBRAND FACTOR;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER STAGING; CELL TYPE; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; GASTROINTESTINAL GLAND; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LASER MICRODISSECTION; MASS SPECTROMETRY; PERICYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; RECTUM MUCOSA; STROMA; TUMOR VASCULARIZATION; TWO DIMENSIONAL ELECTROPHORESIS;

EID: 84860870241     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-8-16     Document Type: Article

References (40)

1. Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging. O'Connell JB, Maggard MA, Ko CY, J Natl Cancer Inst 2004 96 1420 1425 10.1093/jnci/djh275 15467030 (Pubitemid 39429665)
2. Detection and clinical significance of occult tumour cells in colorectal cancer. Tsavellas G, Patel H, Allen-Mersh TG, Br J Surg 2001 88 1307 1320 10.1046/j.0007-1323.2001.01863.x 11578283 (Pubitemid 32955408)
3. Identification of early-stage colorectal cancer patients at risk of relapse post-resection by immunobead reverse transcription-PCR analysis of peritoneal lavage fluid for malignant cells. Lloyd JM, McIver CM, Stephenson SA, Hewett PJ, Rieger N, Hardingham JE, Clin Cancer Res 2006 12 417 423 10.1158/1078-0432.CCR-05-1473 16428481 (Pubitemid 43166130)
4. Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. Hsu JY, Wakelee HA, BioDrugs 2009 23 289 304 10.2165/11317600-000000000-00000 19754219
5. Role of tissue stroma in cancer cell invasion. De Wever O, Mareel M, J Pathol 2003 200 429 447 10.1002/path.1398 12845611 (Pubitemid 36818244)
6. Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. Brown LF, Guidi AJ, Schnitt SJ, Van De Water L, Iruela-Arispe ML, Yeo TK, Tognazzi K, Dvorak HF, Clin Cancer Res 1999 5 1041 1056 10353737 (Pubitemid 29233218)
7. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR, Cancer Res 1999 59 5002 5011 10519415 (Pubitemid 29472907)
8. Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology. Karagiannis GS, Pavlou MP, Diamandis EP, Mol Oncol 2010 4 496 510 10.1016/j.molonc.2010.09.001 20934395
9. Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Sugiyama Y, Farrow B, Murillo C, Li J, Watanabe H, Sugiyama K, Evers BM, Gastroenterology 2005 128 480 486 10.1053/j.gastro.2004.11.010 15685558 (Pubitemid 40431099)
10. Application of laser capture microdissection and proteomics in colon cancer. Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI, Mol Pathol 2001 54 253 258 10.1136/mp.54.4.253 11477141 (Pubitemid 32730402)
11. A mass spectrometry compatible silver staining method for protein incorporating a new silver sensitizer in sodium dodecyl sulfate-polyacrylamide electrophoresis gels. Jin LT, Hwang SY, Yoo GS, Choi JK, Proteomics 2006 6 2334 2337 10.1002/pmic.200500596 16493709
12. Proteomics Identification of Desmin as a Potential Oncofetal Diagnostic and Prognostic Biomarker in Colorectal Cancer. Ma Y, Peng J, Liu W, Zhang P, Huang L, Gao B, Shen T, Zhou Y, Chen H, Chu Z, et al. Mol Cell Proteomics 2009 8 1878 1890 10.1074/mcp.M800541-MCP200 19460759
13. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, Coffey RJ, Caprioli RM, Proteomics 2004 4 793 811 10.1002/pmic.200300635 14997500 (Pubitemid 38339157)
14. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Alfonso P, Nunez A, Madoz-Gurpide J, Lombardia L, Sanchez L, Casal JI, Proteomics 2005 5 2602 2611 10.1002/pmic.200401196 15924290 (Pubitemid 40966487)
15. Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Álvarez-Chaver P, Rodríguez-Pĩeiro AM, Rodríguez-Berrocal FJ, Martínez-Zorzano VS, Páez de la Cadena M, Int J Biochem Cell Biol 2007 39 529 540 10.1016/j.biocel.2006.10.001 17084656 (Pubitemid 46096790)
16. Stromal myofibroblasts are drivers of invasive cancer growth. De Wever O, Demetter P, Mareel M, Bracke M, Int J Cancer 2008 123 2229 2238 10.1002/ijc.23925 18777559
17. Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Kunz-Schughart LA, Knuechel R, Histol Histopathol 2002 17 599 621 11962761 (Pubitemid 34411214)
18. Cancer associated fibroblasts in cancer pathogenesis. Franco OE, Shaw AK, Strand DW, Hayward SW, Semin Cell Dev Biol 2010 21 33 39 10.1016/j.semcdb.2009. 10.010 19896548
19. Colonic pericrypt sheath cells: characterisation of cell type with new monoclonal antibody. Richman PI, Tilly R, Jass JR, Bodmer WF, J Clin Pathol 1987 40 593 600 10.1136/jcp.40.6.593 3301906 (Pubitemid 17092837)
20. Stromal Cells Promote Angiogenesis and Growth of Human Prostate Tumors in a Differential Reactive Stroma (DRS) Xenograft Model. Tuxhorn JA, McAlhany SJ, Dang TD, Ayala GE, Rowley DR, Cancer Res 2002 62 3298 3307 12036948 (Pubitemid 34602428)
21. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Schmitt-Graff A, Desmouliere A, Gabbiani G, Virchows Arch 1994 425 3 24 7921410 (Pubitemid 24295501)
22. Pericyte involvement in capillary sprouting during angiogenesis in situ. Nehls V, Denzer K, Drenckhahn D, Cell Tissue Res 1992 270 469 474 10.1007/BF00645048 1283113
23. Desmin-positive stellate cells associated with angiogenesis in a tumour and non-tumour system. Verhoeven D, Buyssens N, Virchows Arch B Cell Pathol Incl Mol Pathol 1988 54 263 272 2451344 (Pubitemid 18070998)
24. The pericyte - A review. Sims DE, Tissue & Cell 1986 18 153 174 22211247
25. Focal adhesion assembly in myofibroblasts fosters a microenvironment that promotes tumor growth. Kang N, Yaqoob U, Geng Z, Bloch K, Liu C, Gomez T, Billadeau D, Shah V, Am J Pathol 2010 177 1888 1900 10.2353/ajpath.2010.100187 20802179
26. Three-dimensional, quantitative analysis of desmin and smooth muscle alpha actin expression during angiogenesis. Brey EM, McIntire LV, Johnston CM, Reece GP, Patrick CW Jr, Ann Biomed Eng 2004 32 1100 1107 15446506
27. PDGFR[beta]+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G, Nat Cell Biol 2005 7 870 879 10.1038/ncb1288 16113679 (Pubitemid 41486287)
28. Endothelial/pericyte interactions. Armulik A, Abramsson A, Betsholtz C, Circ Res 2005 97 512 523 10.1161/01.RES.0000182903.16652.d7 16166562 (Pubitemid 41361741)
29. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Raza A, Franklin MJ, Dudek AZ, Am J Hematol 2010 85 593 598 10.1002/ajh.21745 20540157
30. Endothelial-pericyte interactions in angiogenesis. Gerhardt H, Betsholtz C, Cell Tissue Res 2003 314 15 23 10.1007/s00441-003-0745-x 12883993 (Pubitemid 37409909)
31. A comparative study of endothelial cell markers expressed in chronically inflamed human tissues: MECA-79, Duffy antigen receptor for chemokines, von Willebrand factor, CD31, CD34, CD105 and CD146. Middleton J, Americh L, Gayon R, Julien D, Mansat M, Mansat P, Anract P, Cantagrel A, Cattan P, Reimund JM, et al. J Pathol 2005 206 260 268 10.1002/path.1788 15887283 (Pubitemid 40903190)
32. Fibroblastic reaction and vascular maturation in human colon cancers. Schmid SA, Dietrich A, Schulte S, Gaumann A, Kunz-Schughart LA, Int J Radiation Biol 2009 85 1013 1025 10.3109/09553000903258897
33. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E, J Clin Invest 1999 103 159 165 10.1172/JCI5028 9916127 (Pubitemid 29053133)
34. Analysis of mural cell recruitment to tumor vessels. Abramsson A, Berlin O, Papayan H, Paulin D, Shani M, Betsholtz C, Circulation 2002 105 112 117 10.1161/hc0102.101437 11772885 (Pubitemid 34049151)
35. Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Gee MS, Procopio WN, Makonnen S, Feldman MD, Yeilding NM, Lee WM, Am J Pathol 2003 162 183 193 10.1016/S0002-9440(10) 63809-6 12507901 (Pubitemid 36042000)
36. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Jain RK, Nat Med 2001 7 987 989 10.1038/nm0901-987 11533692 (Pubitemid 32937367)
37. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. (Special Issue on Targeted Therapy)(fluorouracil). Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz H-J, Oncology 2008 22 456 462 18472617
38. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C, Int J Cancer 2007 121 2606 2614 10.1002/ijc.22999 17691110 (Pubitemid 350136402)
39. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM, Faseb J 2001 15 1239 1241 11344100
40. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Schadendorf D, J Exp Med 2010 207 491 503 10.1084/jem.20091846 20194633